Printer Friendly

GLIATECH AWARDED SBIR GRANT; MONEYS TO FUND ALZHEIMER'S RESEARCH

 CLEVELAND, Feb. 8 /PRNewswire/ -- Gliatech Inc., the neuroscience-based pharmaceutical company, today announced it has been awarded a Phase I Small Business Innovation Research (SBIR) grant.
 The $50,000 grant from the National Institute on Aging is to investigate the roles of microglia and astrocytes in the progression of Alzheimer's disease. The hallmark of Alzheimer's disease is the presence of senile plaques, with a principle component of the plaque being B-amyloid peptide (BAP). Senile plaques can be distinguished from other brain plaques by the presence of microglia and astrocytes, suggesting that glial cells play an integral role in the progression and symptomology of Alzheimer's disease.
 "The identification of BAP receptors on glial cells of the brain and the determination of the effects of BAP binding to these receptors could reveal potential sites for therapeutic intervention," said Thomas O. Oesterling, president and CEO. "An example would be receptor antagonists that would inhibit binding of BAP to glial cells, thereby halting the progression of the disease."
 This grant brings total awards from the NIH to over $1.1 million.
 Gliatech was formed in 1988 to discover, develop and commercialize products and therapies based on an understanding of properties of glial cells, a major component of the nervous system.
 -0- 2/8/93
 /CONTACT: Thomas O. Oesterling, Ph.D., president, Gliatech, 216-831-3200, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, Inc., for Gliatech, 212-979-9180/


CO: Gliatech Inc. ST: Ohio IN: MTC SU:

MH-TW -- NY024 -- 3943 02/08/93 09:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 8, 1993
Words:249
Previous Article:U.S. TEA SALES TOP $1 BILLION FOR SECOND CONSECUTIVE YEAR
Next Article:PACIFIC HORIZON MUTUAL FUND ASSETS INCREASED BY 83 PERCENT IN 1992
Topics:


Related Articles
CEPHALON, INC. RECEIVES SBIR GRANT FROM THE NIH TO RESEARCH NOVEL THERAPEUTICS FOR BRAIN AND SPINAL CORD NERVE DAMAGE AND DEGENERATION
GLIATECH AWARDED NIH GRANT FOR NOVEL APPROACH TO ALZHEIMER'S DISEASE; RESEARCH PINPOINTS DISRUPTION OF BRAIN'S IMMUNE SYSTEM
GLIATECH AWARDED NIH GRANT TO DEVELOP PRODUCT TO TREAT ATTENTION DEFICIT DISORDER
GLIATECH REPORTS FIRST-QUARTER RESULTS
Gliatech Awarded $100,000 Phase I SBIR Grant to Clone Histamine H3 Receptor
Gliatech Announces Second Quarter 1999 Financial Results.
Gliatech Announces Third Quarter 1999 Financial Results.
Gliatech Announces Third Quarter 2001 Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters